Adicet Bio (FRA:1IJ) Shares Outstanding (EOP): 9.60 Mil (As of Mar. 2026)


FRA:1IJ Adicet Bio Inc FRA:1IJ
31 GF Score
Price €7.50
! 2 Warning Signs
View Full Analysis

What is Adicet Bio Shares Outstanding (EOP)?

Adicet Bio FRA:1IJ -3.85% 31 Shares Outstanding (EOP) is 9.60 Mil as of Mar. 2026. GuruFocus rates FRA:1IJ with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Adicet Bio's shares outstanding for the quarter that ended in Mar. 2026 was 9.60 Mil.

Adicet Bio's quarterly shares outstanding increased from Dec. 2025 (9.59 Mil) to Mar. 2026 (9.60 Mil). It means Adicet Bio issued new shares from Dec. 2025 to Mar. 2026 .

Adicet Bio's annual shares outstanding increased from Dec. 2024 (5.16 Mil) to Dec. 2025 (9.59 Mil). It means Adicet Bio issued new shares from Dec. 2024 to Dec. 2025 .


Adicet Bio  (FRA:1IJ) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Adicet Bio Shares Outstanding (EOP) Related Terms


Adicet Bio Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Adicet Bio's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio Shares Outstanding (EOP) Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial 2.48 2.69 2.70 5.16 9.59

Adicet Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.17 5.20 5.20 9.59 9.60

FRA:1IJ vs EDSA, GOSS, HRTX: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Adicet Bio's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adicet Bio Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Shares Outstanding (EOP) falls into.


FRA:1IJ
31GF Score
Adicet Bio Inc FRA:1IJ
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 9.60 Mil mean?
Adicet Bio (FRA:1IJ) has a Shares Outstanding (EOP) of 9.60 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Adicet Bio and its competitors.
Is Adicet Bio's Shares Outstanding (EOP) too high?
Adicet Bio's current Shares Outstanding (EOP) is 9.60 Mil. Overall, Adicet Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Shares Outstanding (EOP) compare to EDSA and GOSS?
Adicet Bio's Shares Outstanding (EOP) of 9.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Adicet Bio and its competitors. Adicet Bio's current Shares Outstanding (EOP) is 9.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (FRA:1IJ) has a current Shares Outstanding (EOP) of 9.60 Mil. The current Shares Outstanding (EOP) is 9.60 Mil. Adicet Bio's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Adicet Bio (FRA:1IJ), the current Shares Outstanding (EOP) is 9.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adicet Bio Business Description

Other Exchanges ACET:USA0HX7:UK
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for FRA:1IJ

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.50
Price